Singapore In 2020, the FDA granted its first approval to a comprehensive liquid biopsy, potentially representing a paradigm shift towards using liquid biopsies upfront as an easier, safer, faster, and more effective tool for diagnosing cancer patients than traditional invasive tissue biopsies. The company behind the Guardant360® CDx test, Guardant…
Singapore Simranjit Singh highlights Guardant Health’s role in the global precision oncology landscape and how the company leverages its proprietary blood tests, vast data sets, and advanced analytics across the huge AMEA region. Singh also touches on the significance of a recent US FDA approval for its comprehensive liquid biopsy and…
See our Cookie Privacy Policy Here